Gilead's base business sales rose 16% year over year, and it raised its full-year revenue forecast by $1.6 billion. Growth in HIV and Trodelvy supports the business, though future IRA-related price pressure on Biktarvy is a concern.
Growth spans HIV, breast cancer, and Livdelzi, so it is not tied to one drug. Future price pressure on Biktarvy from the IRA is a concern. The broad sales gains and higher full-year revenue forecast support a positive reading despite that concern.
Follow Gilead Sciences (GILD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GILD